Meng Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meng Liang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Zhifang Wu
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, People’s Republic of China
3 shared publications Bo Wu
Department of Urinary Surgery, First Hospital of Shanxi Medical University, Taiyuan, China
1 shared publication- Caozhe Cui
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, People’s Republic of China
1 shared publication - Fang Hao
Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, People’s Republic of China
1 shared publication - Hongliang Wang
Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, People’s Republic of China
1 shared publication - Jianbo Cao
Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, People’s Republic of China
1 shared publication
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (12) , 1099-1101
Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities
Lecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear. We report 3 patients with comparable clinical backgrounds and similar baseline cognitive performance who underwent amyloid-β PET before and after lecanemab treatment. Quantitative analysis using Centiloid showed a greater reduction in amyloid burden in the patient who developed ARIA than in the 2 patients without ARIA. These observations suggest ARIA may be associated with more pronounced treatment-related amyloid clearance, warranting further investigation in larger cohorts.
- 20 October 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (12) , 1099-1101
Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities
Lecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear. We report 3 patients with comparable clinical backgrounds and similar baseline cognitive performance who underwent amyloid-β PET before and after lecanemab treatment. Quantitative analysis using Centiloid showed a greater reduction in amyloid burden in the patient who developed ARIA than in the 2 patients without ARIA. These observations suggest ARIA may be associated with more pronounced treatment-related amyloid clearance, warranting further investigation in larger cohorts.
- Open Access
- 4 September 2026
- Published by Springer Nature in EJNMMI Research
18F-PSMA-1007 PET/CT in PSMA-avid bladder urothelial carcinoma with extensive bone metastases: a case report
- 4 September 2026
- Published by Springer Nature in EJNMMI Research
Open Access18F-PSMA-1007 PET/CT in PSMA-avid bladder urothelial carcinoma with extensive bone metastases: a case report